NY-MORROW-SODALI
26.4.2022 15:02:06 CEST | Business Wire | Press release
Morrow Sodali, the leading global shareholder engagement and governance advisory firm, announced today that TPG Growth, the middle market and growth equity platform of alternative asset firm TPG, has acquired a majority stake in the company. The partnership with TPG will significantly advance Morrow Sodali’s mission of providing clients worldwide with unrivaled strategic advice and comprehensive support, enabling them to maximize value and expertly manage stakeholder relations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220426005374/en/
TPG’s investment coincides with Morrow Sodali’s 50th anniversary, which the company is celebrating with a series of special initiatives centered on the theme of “Building Together”. Throughout the year, Morrow Sodali will highlight the Company’s best-in-class expertise on emerging global trends in shareholder engagement matters impacting corporations, including ESG reporting, sustainability, climate change, board composition and evaluation, succession planning, executive compensation, shareholder activism and investor engagement.
Alvise Recchi, Chief Executive Officer of Morrow Sodali, said: "We are thrilled to become a TPG portfolio company. Joining forces with an organization of TPG's strength and breadth will allow us to further enhance our market leadership position, forged over decades of guiding clients through every critical trend impacting corporations, shareholders, and the financial markets. Our focus is on delivering value creation and as we move forward with TPG’s backing, we’ll grow that value for our clients, especially as they increase their focus on corporate purpose and the goals of diversity, inclusiveness, and sustainability.”
Ransom Langford, Partner at TPG, added: "Morrow Sodali’s differentiated ability to deliver results for its diverse set of clients, combined with a commitment to its values of integrity, excellence, collaboration, innovation and respect creates a unique opportunity for our partnership. As the focus on ESG continues to increase amongst companies and investors alike, Morrow Sodali has established itself as a trusted partner and global leader in proactive and trusted shareholder engagement. We look forward to working with the Morrow Sodali team to continue investing in the business’ extensive breadth of services and capabilities across the shareholder lifecycle."
Morrow Sodali recently secured the #1 position in 2021 M&A league tables released by both Mergermarket and The Deal. Morrow Sodali has made several highly strategic, global acquisitions and personnel investments, and, with the support of TPG, expects to accelerate those efforts.
ABOUT MORROW SODALI
Morrow Sodali is a global corporate advisory firm focused on shareholder engagement. The Company provides clients with comprehensive services relating to corporate governance , diversity equity & inclusion, sustainability, proxy solicitation , capital markets intelligence , shareholder and bondholder engagement, M&A , shareholder activism and contested situations .
Headquartered in New York and with offices in London, Sydney, Buenos Aires, Frankfurt, Hong Kong, Madrid, Melbourne, Paris, Rome, Sao Paolo, Seoul, Stamford, Toyko and Toronto, Morrow Sodali serves more than 850 clients in 80+ countries, including many of the world’s largest multinational corporations. Clients include publicly-listed and private companies, mutual fund groups, stock exchanges and membership associations. For more information about Morrow Sodali, please visit www.morrowsodali.com .
ABOUT TPG GROWTH
TPG Growth is the middle market and growth equity investment platform of TPG, the global alternative asset firm. With approximately $14.7 billion of assets under management, TPG Growth targets investments in a broad range of industries and geographies. TPG Growth has the deep sector knowledge, operational resources, and global experience to drive value creation, and help companies reach their full potential. The platform is backed by the resources of TPG, which has approximately $114 billion of assets under management. For more information, please visit www.tpg.com or on Twitter @TPG.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220426005374/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 20266.7.2026 13:30:00 CEST | Press release
Fully enrolled 123-patient Phase 1b cohort demonstrated 21.2-month median overall survival, 33% three-year overall survival, and a survival curve plateau beyond two yearsData presented in a heavily pretreated population where durable long-term survival is rarely reported17% of patients alive and off all systemic anticancer therapy at last follow-upExtended safety follow-up showed no new safety signals, no treatment-related deaths, and 98% resolution of immune-mediated diarrhea/colitis Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year landmark Phase 1b data from the fully enrolled C-800-01 cohort evaluating botensilimab (BOT), an Fc-enhanced multifunctional anti–CTLA-4 antibody, plus balstilimab (BAL), an anti–PD-1 antibody, in patients with refractory microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases. The data were presented at the European Society for Medical Oncology Gastrointestinal Cancers (E
LTM Launches BlueVerse™ RightLogic to Address Cyber Risk in AI Era6.7.2026 11:12:00 CEST | Press release
New assessment and risk assurance framework helps enterprises gain unified visibility, prioritise remediation and scale AI securely LTM, the Business Creativity partner to the world’s largest enterprises, has launched BlueVerse™ RightLogic, a cybersecurity assessment and risk assurance framework designed to help enterprises identify, assess and remediate cyber exposure as they accelerate AI adoption. AI is now capable of autonomously identifying and exploiting vulnerabilities, while exposure across infrastructure, applications and supply chains continue to expand. This has elevated cyber risk from a technology concern to a board-level priority, with enterprises struggling to maintain visibility and respond at the speed of emerging threats. BlueVerse RightLogic addresses this gap by providing a unified, business-aligned view of enterprise exposure and enabling a shift from fragmented, point-in-time assessments to continuous, evidence-led risk management. The framework combines an end-to
Media Release: Financial Worries Rise and Match Health Concerns as Cost-of-Living Pressures Mount in 20266.7.2026 10:00:00 CEST | Press release
Globally, people are united in their top personal worries: Financial and health issues rank at the top in 2026, averaging 13 percentage points ahead of other concerns.Financial pressure is prominent across Europe, rising in France, Germany, and U.K., and emerging as a top concern in newly measured markets, Spain and Switzerland.Allianz published these results in “The Allianz 3am Report 2026,” which surveyed 10,000 people across 10 countries worldwide about what keeps them awake at night.Addressing financial concerns requires accessible, targeted financial and risk education. To support this, Allianz has launched the “Allianz School For Life” learning platform. Households around the world are feeling the strain of the rising cost of living, with financial pressure increasingly shaping everyday choices and long-term confidence. Finances and health are now tied as the top global worries, at 48% each, followed by concerns about the future at 35%, according to consumer surveys in 10 countri
HAZAMA ANDO Becomes an Official Partner in Helical Fusion’s Commercial Fusion Initiative and Signs MoU Toward Construction of the Fusion Pilot Plant6.7.2026 08:40:00 CEST | Press release
A long-established Japanese general contractor will contribute construction expertise to advance Fusion Pilot Plant development toward commercially viable fusion power. Helical Fusion Co., Ltd. (“Helical Fusion”), a Japan-based fusion energy startup developing fusion power plants, and HAZAMA ANDO CORPORATION (“HAZAMA ANDO”), a long-established Japanese general contractor, today announced that HAZAMA ANDO has become an Official Partner in the Helix Program, Helical Fusion’s commercial fusion initiative. The two companies have also signed a memorandum of understanding (“MoU”) to collaborate toward the construction of Helix KANATA, Helical Fusion’s Fusion Pilot Plant targeted for the 2030s. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706176052/en/ (L-R) Kazuhiko Kuniya (Representative Director and President, HAZAMA ANDO CORPORATION) and Takaya Taguchi (Co-Founder and CEO, Helical Fusion Co., Ltd.) at a press conference in
Sofinnova Partners Announces Myricx Bio Agrees to Be Acquired by Novartis6.7.2026 07:15:00 CEST | Press release
Sofinnova Partners co-led the seed investment in 2019 and has supported the company from founding through to exitThe proposed acquisition combines the oncology expertise of Novartis with Myricx Bio’s novel ADC assets and platform having broad potential across multiple solid tumor typesMyricx Bio's first-in-class NMTi payload platform is designed to improve the therapeutic index of ADCs, offering the potential for more effective and better-tolerated treatment options for cancer patientsThe transaction valued at up to $1.5 billion including $1.1 billion cash upfront Sofinnova Partners, a leading European life sciences venture capital firm, today announced that its portfolio company Myricx Bio (“Myricx”) has reached agreement to be acquired by Novartis, for up to $1.5 billion including $1.1 billion cash upfront plus potential milestone payments. This marks Sofinnova Partners' seventh exit in three years. Myricx Bio is a UK-headquartered transatlantic biotech company focused on the discove
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom